JP2019187429A5 - - Google Patents

Download PDF

Info

Publication number
JP2019187429A5
JP2019187429A5 JP2019113661A JP2019113661A JP2019187429A5 JP 2019187429 A5 JP2019187429 A5 JP 2019187429A5 JP 2019113661 A JP2019113661 A JP 2019113661A JP 2019113661 A JP2019113661 A JP 2019113661A JP 2019187429 A5 JP2019187429 A5 JP 2019187429A5
Authority
JP
Japan
Prior art keywords
disease
ischemia
cells
cell
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019113661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019187429A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019187429A publication Critical patent/JP2019187429A/ja
Publication of JP2019187429A5 publication Critical patent/JP2019187429A5/ja
Priority to JP2021156680A priority Critical patent/JP2021191311A/ja
Priority to JP2023017468A priority patent/JP2023053019A/ja
Withdrawn legal-status Critical Current

Links

JP2019113661A 2011-12-02 2019-06-19 増強された幹細胞組成物 Withdrawn JP2019187429A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021156680A JP2021191311A (ja) 2011-12-02 2021-09-27 増強された幹細胞組成物
JP2023017468A JP2023053019A (ja) 2011-12-02 2023-02-08 増強された幹細胞組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566492P 2011-12-02 2011-12-02
US61/566,492 2011-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018244311A Division JP6775568B2 (ja) 2011-12-02 2018-12-27 増強された幹細胞組成物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020202687A Division JP2021036918A (ja) 2011-12-02 2020-12-07 増強された幹細胞組成物
JP2021156680A Division JP2021191311A (ja) 2011-12-02 2021-09-27 増強された幹細胞組成物

Publications (2)

Publication Number Publication Date
JP2019187429A JP2019187429A (ja) 2019-10-31
JP2019187429A5 true JP2019187429A5 (https=) 2020-01-09

Family

ID=48536037

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014544868A Active JP6220791B2 (ja) 2011-12-02 2012-11-29 増強された幹細胞組成物
JP2017098749A Active JP6483187B2 (ja) 2011-12-02 2017-05-18 増強された幹細胞組成物
JP2018244311A Active JP6775568B2 (ja) 2011-12-02 2018-12-27 増強された幹細胞組成物
JP2019113661A Withdrawn JP2019187429A (ja) 2011-12-02 2019-06-19 増強された幹細胞組成物
JP2020202687A Pending JP2021036918A (ja) 2011-12-02 2020-12-07 増強された幹細胞組成物
JP2021156680A Pending JP2021191311A (ja) 2011-12-02 2021-09-27 増強された幹細胞組成物
JP2023017468A Pending JP2023053019A (ja) 2011-12-02 2023-02-08 増強された幹細胞組成物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2014544868A Active JP6220791B2 (ja) 2011-12-02 2012-11-29 増強された幹細胞組成物
JP2017098749A Active JP6483187B2 (ja) 2011-12-02 2017-05-18 増強された幹細胞組成物
JP2018244311A Active JP6775568B2 (ja) 2011-12-02 2018-12-27 増強された幹細胞組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020202687A Pending JP2021036918A (ja) 2011-12-02 2020-12-07 増強された幹細胞組成物
JP2021156680A Pending JP2021191311A (ja) 2011-12-02 2021-09-27 増強された幹細胞組成物
JP2023017468A Pending JP2023053019A (ja) 2011-12-02 2023-02-08 増強された幹細胞組成物

Country Status (9)

Country Link
US (4) US9452186B2 (https=)
EP (2) EP2785834B1 (https=)
JP (7) JP6220791B2 (https=)
CN (3) CN112410298A (https=)
AU (1) AU2012321088B8 (https=)
CA (1) CA2857640C (https=)
ES (1) ES2836976T3 (https=)
PT (1) PT2785834T (https=)
WO (1) WO2013082243A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス,インコーポレイテッド 増強された幹細胞組成物
EP2785350B1 (en) * 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
DK2838533T3 (da) 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) * 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
AU2015217142B2 (en) * 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
US20180112180A1 (en) * 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN107921025A (zh) 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
WO2017059281A1 (en) * 2015-10-02 2017-04-06 Mcquillan Sharon Patrica Adipose-derived stem cell product
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
US11525119B2 (en) 2016-09-06 2022-12-13 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
WO2018070819A1 (ko) * 2016-10-14 2018-04-19 제주대학교 산학협력단 시클레소나이드를 포함하는, 암 줄기세포 성장 억제용 조성물
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
JP7586811B2 (ja) 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
CN113069460B (zh) * 2021-03-24 2022-02-08 兰州大学 哈西奈德及其衍生物用于制备治疗和/或预防脑血管疾病药物中的应用
CN114848675A (zh) * 2022-06-24 2022-08-05 南开大学 Pge2赋能的间充质干细胞制剂在制备治疗肺损伤药物中的应用
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds
WO2025155768A1 (en) * 2024-01-17 2025-07-24 Rhode Island Hospital A motile injectable cell that accelerates musculoskeletal connective tissue repair

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4839032B1 (https=) 1964-09-11 1973-11-21
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
DK0423980T3 (da) 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
AU2882992A (en) 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
JP2795014B2 (ja) 1991-11-29 1998-09-10 東洋インキ製造株式会社 保存温度管理用インジケーター
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5442033A (en) 1993-07-20 1995-08-15 Ethicon, Inc. Liquid copolymers of epsilon-caprolactone and lactide
AU702871B2 (en) 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5753516A (en) 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
US5709472A (en) 1995-10-23 1998-01-20 Lifelines Technology, Inc. Time-temperature indicator device and method of manufacture
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US6191109B1 (en) 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
ES2207762T3 (es) 1998-01-05 2004-06-01 Mitra Industries Limited Bolsa de sangre flexible colappsable.
IL125532A0 (en) * 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6946293B1 (en) 1999-02-10 2005-09-20 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
RU2259830C2 (ru) 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
ATE464373T1 (de) 2001-12-21 2010-04-15 Mount Sinai Hospital Corp Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
EP1348758A1 (en) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells
RU2205627C1 (ru) 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
CA2518193A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
US20050054103A1 (en) 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
JP2007525429A (ja) 2003-03-11 2007-09-06 キューエルティー ユーエスエー,インコーポレイテッド. 細胞スケジュール依存性抗癌剤のための処方
EP1613742A2 (en) * 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005065396A2 (en) 2003-12-31 2005-07-21 Osteotech, Inc. Improved bone matrix compositions and methods
JP2005220089A (ja) 2004-02-06 2005-08-18 Menicon Co Ltd 組織等価物用パッケージ
US20050176140A1 (en) 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
US7004621B2 (en) 2004-06-17 2006-02-28 Cryovac, Inc. Method of monitoring temperature exposure
JP4086816B2 (ja) 2004-07-01 2008-05-14 株式会社Nec情報システムズ Bga部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
ZA200704252B (en) * 2004-10-25 2009-09-30 Cellerant Therapeutics Inc Methods of expanding myeloid cell populations and uses thereof
JP2008518013A (ja) 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンep4アゴニストによる処置方法およびデリバリー方法
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
JP4839032B2 (ja) * 2005-07-13 2011-12-14 国立大学法人 岡山大学 ケモカイン受容体作用増強剤
JP2009514967A (ja) 2005-11-07 2009-04-09 ザ ジェネラル ホスピタル コーポレーション 幹細胞の加齢化を調節するための方法及び組成物
AU2006326853B2 (en) 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
ES2477874T3 (es) 2006-02-08 2014-07-18 Becton, Dickinson And Company Sistema y método para dispositivos de recogida de muestras de sangre
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
US7819934B2 (en) 2006-07-14 2010-10-26 Xcellerex, Inc. Environmental containment systems
US20100233135A1 (en) 2006-08-16 2010-09-16 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
WO2008056963A1 (en) 2006-11-10 2008-05-15 Chanil Moon Method for proliferating stem cells with leptin
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
WO2009134532A2 (en) 2008-03-07 2009-11-05 The Trustees Of Columbia University In The City Of New York Homing in mesenchymal stem cells
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
RU2497532C2 (ru) 2008-12-03 2013-11-10 Эморсайт, Инк. Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
EP2275442A1 (en) * 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス,インコーポレイテッド 増強された幹細胞組成物
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia

Similar Documents

Publication Publication Date Title
JP2019187429A5 (https=)
JP2021036918A5 (https=)
Pyšná et al. Endothelial progenitor cells biology in diabetes mellitus and peripheral arterial disease and their therapeutic potential
Nguyen et al. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature
Patel et al. The role of endothelial cells and their progenitors in intimal hyperplasia
Przybyt et al. Mesenchymal stem cells: promising for myocardial regeneration?
JP2015504313A5 (https=)
Castro et al. Cellular and molecular heterogeneity associated with vessel formation processes
JP2015505829A5 (https=)
RU2010116271A (ru) Ангиогенные клетки из плацентарного перфузата человека
Oh et al. Challenges to success in heart failure: cardiac cell therapies in patients with heart diseases
RU2011111938A (ru) Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
Jiang et al. Progress in stem cell therapy for the diabetic foot
Obi et al. Effects of shear stress on endothelial progenitor cells
Lilyanna et al. Cord lining-mesenchymal stem cells graft supplemented with an omental flap induces myocardial revascularization and ameliorates cardiac dysfunction in a rat model of chronic ischemic heart failure
Athanassopoulos et al. Microvessel networks in pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissues
Siepe et al. Stem cell research and cell transplantation for myocardial regeneration
Wang et al. Regenerative therapy for cardiomyopathies
Loisel et al. Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?
Suzuki et al. Omentopexy enhances graft function in myocardial cell sheet transplantation
Maeda et al. Impact of mesenchymal stromal cell delivery through cardiopulmonary bypass on postnatal neurogenesis
Turksen Adult stem cells and cardiac regeneration
He et al. Recent advances in mesenchymal stem cell therapy for myocardial infarction
Biscetti et al. The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1)
Tonkin et al. Healing the ischaemic heart: a critical review of stem cell therapies